Posted by Michael Wonder on 27 Apr 2022
European Medicines Agency grants PRIME designation to BioCryst’s ALK-2 inhibitor, BCX9250, for treatment of fibrodysplasia ossificans progressiva
27 April 2022 - BCX9250 is first investigational drug for FOP to be eligible for program.
BioCryst Pharmaceuticals today announced the EMA has granted access to the Priority Medicines (PRIME) scheme for BCX9250, a novel, oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst for the treatment of fibrodysplasia ossificans progressiva.
